There is vast therapeutic potential for CCH for many medical conditions caused by excess collagen accumulation.

Excess collagen causes many medical conditions, and consequently BioSpecifics believes that minimally invasive collagenase therapy has wide potential therapeutic applications. BioSpecifics has explored the use of collagenase in a multitude of medical conditions and in both topical and injectable forms. BioSpecifics developed, marketed, and later sold to another company, a topical product, Santyl®, for wound treatment which has been very successful and used in millions of patients. The Company now focuses on injectable collagenase which is marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU and is in clinical development for several other promising indications.

There are many potential advantages to the clinical use of CCH. The the delivery of therapeutic CCH is minimally invasive and it can be administered in an office setting. CCH holds considerable therapeutic potential to change the way patients are treated for a range of diseases and indications where surgery is currently the only proven option for removal of the scar tissue. New clinical indications involving the therapeutic application of clostridial collagenase to supplement the body’s own natural enzymes are continuously being proposed by specialists in the medical community.